Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors

US8071616B2 · kind B2 · utility

Assignee

• BAYER HEALTHCARE LLC · DE

Inventors

• Jacques Dumas · Neuilly-Plaisance, FR
• William Scott · Guilford, US
• Bernd Riedl · Wuppertal, DE

Key dates

• Filing date: Jan 25, 2010
• Grant date: Dec 6, 2011
• Expiry date: Jan 25, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D217/08
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

This invention relates to urea compounds containing a pyridine, quinoline, or isoquinoline functionality which is oxidized at the nitrogen heteroatom and which are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.